MXPA04010054A - Metodo para tratar y prevenir hiperparatiroidismo. - Google Patents

Metodo para tratar y prevenir hiperparatiroidismo.

Info

Publication number
MXPA04010054A
MXPA04010054A MXPA04010054A MXPA04010054A MXPA04010054A MX PA04010054 A MXPA04010054 A MX PA04010054A MX PA04010054 A MXPA04010054 A MX PA04010054A MX PA04010054 A MXPA04010054 A MX PA04010054A MX PA04010054 A MXPA04010054 A MX PA04010054A
Authority
MX
Mexico
Prior art keywords
treating
deficiency
preventing
vitamin
arvdd
Prior art date
Application number
MXPA04010054A
Other languages
English (en)
Inventor
A Strugnell Stephen
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of MXPA04010054A publication Critical patent/MXPA04010054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

Esta invencion se relaciona a un metodo para tratar o prevenir hiperparatiroidismo asociado con el envejecimiento y/o con el sindrome de Deficiencia de Vitamina D Relacionado con el Envejecimiento (ARVDD), administrando una cantidad suficiente de un compuesto de vitamina D activa utilizando una variedad de protocolos de tratamiento efectivos. La invencion ademas se relaciona al tratamiento o prevencion de una o mas de las siguientes condiciones, por ejemplo, (1) deficiencia de Vitamina D primaria, (2) deficiencia de 1,25-(OH2D3), y (3) resistencia de 1,25-(OH2D3) incluidas dentro del sindrome de ARVDD.
MXPA04010054A 2002-04-19 2003-04-17 Metodo para tratar y prevenir hiperparatiroidismo. MXPA04010054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/127,005 US20020183288A1 (en) 1995-04-03 2002-04-19 Method for treating and preventing hyperparathyroidism
PCT/US2003/012013 WO2003088976A1 (en) 2002-04-19 2003-04-17 Method for treating and preventing hyperparathyroidism

Publications (1)

Publication Number Publication Date
MXPA04010054A true MXPA04010054A (es) 2004-12-13

Family

ID=29248428

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04010054A MXPA04010054A (es) 2002-04-19 2003-04-17 Metodo para tratar y prevenir hiperparatiroidismo.

Country Status (10)

Country Link
US (2) US20020183288A1 (es)
EP (1) EP1499324A4 (es)
JP (1) JP2005526833A (es)
KR (1) KR20040101530A (es)
CN (1) CN100421667C (es)
AU (1) AU2003225053B2 (es)
CA (1) CA2481120A1 (es)
IL (1) IL164219A0 (es)
MX (1) MXPA04010054A (es)
WO (1) WO2003088976A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
WO2003047595A1 (en) * 2001-12-03 2003-06-12 Novacea, Inc. Pharmaceutical compositions comprising active vitamin d compounds
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
EP3047847A1 (en) * 2005-10-12 2016-07-27 OPKO Renal, LLC Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
CA2640094C (en) 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
CA2651283A1 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
PT3357496T (pt) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Terapia utilizando um agente de repleção de vitamina d e um agente de substituição hormonal de vitamina d
WO2008134518A2 (en) * 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
CN101668532B (zh) * 2007-04-25 2014-08-20 赛特克罗公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的组合物及其相应的制药用途
EP2148683A4 (en) * 2007-04-25 2012-09-12 Proventiv Therapeutics Llc METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYREOSIS IN CHRONIC KIDNEY DISEASE
JP5501956B2 (ja) 2007-04-25 2014-05-28 シトクロマ インコーポレイテッド ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成物
CA2714996C (en) 2008-04-02 2020-04-07 Cytochroma Inc. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US8999169B2 (en) * 2008-10-17 2015-04-07 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
US8153455B2 (en) * 2010-02-01 2012-04-10 Walsin Lihwa Corporation Method for enhancing light extraction efficiency of light emitting diodes
CN105796530A (zh) 2010-03-29 2016-07-27 赛特克罗公司 用于降低甲状旁腺水平的方法和组合物
ES2871021T3 (es) 2010-05-12 2021-10-28 Spectrum Pharmaceuticals Inc Hidróxido de carbonato de lantano, oxicarbonato de lantano y procedimientos de fabricación y uso
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
IL290855B1 (en) 2016-03-28 2024-02-01 Eirgen Pharma Ltd Treatment methods using vitamin D
WO2019124411A1 (ja) * 2017-12-20 2019-06-27 Ｅａファーマ株式会社 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物
RU2697109C1 (ru) * 2018-08-21 2019-08-12 Сергей Николаевич Пампутис Способ прогнозирования эффективности оперативных методов лечения первичного гиперпаратиреоза

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2383446A (en) * 1941-06-04 1945-08-28 Du Pont Antirachitic materials and processes for their production
US3697559A (en) * 1971-02-25 1972-10-10 Wisconsin Alumni Res Found 1,25-dihydroxycholecalciferol
US3741996A (en) * 1971-12-02 1973-06-26 Wisconsin Alumni Res Found 1{60 -hydroxycholecalciferol
US4670190A (en) * 1973-01-10 1987-06-02 Hesse Robert H 1-α-hydroxy vitamin D compounds and process for preparing same
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4181721A (en) * 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4160803A (en) * 1978-03-23 1979-07-10 Corning Glass Works Self packaged test kit
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
JPS5626820A (en) * 1979-08-10 1981-03-16 Chugai Pharmaceut Co Ltd Immunosuppressing agent
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
EP0028484B1 (en) * 1979-10-23 1985-08-14 Teijin Limited Process for the preparation of active-type vitamin d3 compounds and of the cholesta-5,7-diene precursors, and products so obtained
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4508651A (en) * 1983-03-21 1985-04-02 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
US4689180A (en) * 1984-01-30 1987-08-25 Wisconsin Alumni Research Foundation 1α,25-dihydroxy-22Z-dehydroxyvitamin D compound
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
CA1332841C (en) * 1984-11-27 1994-11-01 Noboru Kubodera Vitamin d derivatives and process for producing the same
US4717721A (en) * 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
US4650665A (en) * 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4661294A (en) * 1985-03-18 1987-04-28 The General Hospital Corporation Biologically active 1-thio derivatives of vitamin D
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4749710A (en) * 1985-05-01 1988-06-07 Hoffmann-La Roche Inc. Immunosuppressive agents
CA1317546C (en) * 1985-07-01 1993-05-11 Werner Meier Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US5338532A (en) * 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4870105B1 (en) * 1987-04-07 1998-03-10 Braintree Lab Phosphorus binder
US4902481A (en) * 1987-12-11 1990-02-20 Millipore Corporation Multi-well filtration test apparatus
DE68907483T2 (de) * 1988-04-21 1993-10-21 Leo Pharm Prod Ltd Vitamin d analoge.
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
US5232836A (en) * 1988-05-04 1993-08-03 Ire-Medgenix S.A. Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5869473A (en) * 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1341408C (en) * 1988-08-02 2002-12-10 Charles W. Bishop Method for treating and preventing loss of bone mass
EP0373687B1 (en) * 1988-12-12 1993-06-02 Duphar International Research B.V Method for the photochemical conversion of tachysterol compounds into previtamin d compounds and of trans-vitamin d compounds into cis-vitamin d compounds
US4897388A (en) * 1988-12-20 1990-01-30 Geriatric Research Institute, Inc. Method of treating Alzheimer's disease
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US4948789A (en) * 1989-03-28 1990-08-14 Chugai Seiyaku Kabushiki Kaisha Suppression of parathyroid hormone synthesis and secretion
JP2645130B2 (ja) * 1989-03-31 1997-08-25 日清製粉株式会社 ステロイド誘導体
US5063221A (en) * 1989-04-05 1991-11-05 Chugai Seiyaku Kabushiki Kaisha Treatment for hyperparathyroidism with use of vitamin d derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5219528A (en) * 1989-07-28 1993-06-15 Pierce Chemical Company Apparatus for rapid immunoassays
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
CA2066716A1 (en) * 1989-09-25 1991-03-26 Raymond A. Daynes Use of steroid hormones in compositions for inducing t cell lymphokine production
US5260290A (en) * 1990-02-14 1993-11-09 Wisconsin Alumni Research Foundation Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69110739T2 (de) * 1990-04-27 1995-11-23 Duphar Int Res Verfahren zur photochemischen Isomerisierung von organischen Verbindungen unter dem Einfluss eines Photosensibilisators.
US5141719A (en) * 1990-07-18 1992-08-25 Bio-Rad Laboratories, Inc. Multi-sample filtration plate assembly
US5756783A (en) * 1990-09-21 1998-05-26 Bone Care International, Inc. 1α-Hydroxy-24-EPI-vitamin D4
KR100231809B1 (ko) * 1990-09-21 1999-12-01 로버트 에이. 벡크만 1알파-하이드록시 비타민 d4 및 이의 중간체 및 동족체, 및 이를 포함하는 약제학적 조성물
US5786348A (en) * 1991-01-08 1998-07-28 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
EP0503630B1 (en) * 1991-03-13 1995-12-27 Kuraray Co., Ltd. Cyclohexanetriol derivatives
US5264184A (en) * 1991-03-19 1993-11-23 Minnesota Mining And Manufacturing Company Device and a method for separating liquid samples
US5417923A (en) * 1991-04-24 1995-05-23 Pfizer Inc. Assay tray assembly
ATE143007T1 (de) * 1991-07-05 1996-10-15 Duphar Int Res Vitamin-d derivat, verfahren zu dessen herstellung sowie zwischenprodukte dafür
US5205989A (en) * 1991-09-18 1993-04-27 Minnesota Mining And Manufacturing Company Multi-well filtration apparatus
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
JP3722832B2 (ja) * 1992-06-22 2005-11-30 ルーナー、コーポレーション 経口用１α−ヒドロキシプレビタミンＤ
US5753638A (en) * 1992-10-07 1998-05-19 Hoffmann-La Roche Inc. Method of treating hyperproliferative skin disease with Vitamin D3 fluorinated analogs
GB9223061D0 (en) * 1992-11-04 1992-12-16 Leo Pharm Prod Ltd Chemical compounds
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5449668A (en) * 1993-06-04 1995-09-12 Duphar International Research B.V. Vitamin D compounds and method of preparing these compounds
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5597575A (en) * 1994-06-06 1997-01-28 Breitbarth; Richard Composition for stimulating and inducing hair growth
US5665387A (en) * 1994-09-01 1997-09-09 K.U. Leuven Research & Development Methods and compositions for primary and secondary prevention of autoimmune diabetes
US5559107A (en) * 1994-10-20 1996-09-24 Gates; Stephen Regulation of immune response
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6376479B1 (en) * 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5739271A (en) * 1995-06-07 1998-04-14 Gen-Probe Incorporated Thiocationic lipids
DK0771789T3 (da) * 1995-10-30 2000-06-13 Hoffmann La Roche 1 alpha, 26-dihydroxy-D-homo-vitamin D3
US5691328A (en) * 1996-02-02 1997-11-25 Clarion Pharmaceuticals Inc. Phosphoethanolamine conjugates of vitamin D compounds
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
EP0902687A1 (en) * 1996-03-11 1999-03-24 Focal, Inc. Polymeric delivery of radionuclides and radiopharmaceuticals
DK0949905T3 (da) * 1996-12-20 2001-10-22 Alza Corp Injicertbart depotelpræparat og fremgangsmåde til fremstilling
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6304291B1 (en) * 1997-07-15 2001-10-16 Silverbrook Research Pty Ltd Artcard for the administration of the operation of a camera device
TW367247B (en) * 1998-02-03 1999-08-21 Otsuka Pharma Co Ltd Storage container for Vitamin D solution and transfusion container
ATE515265T1 (de) * 1998-03-27 2011-07-15 Univ Oregon Health & Science Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
BR0113703A (pt) * 2000-09-08 2003-07-22 Wisconsin Alumni Researcg Foun Compostos e métodos de tratamento de psorìase, leucemia, câncer do cólon, do seio ou da próstata, osteodistrofia renal, de doenças auto-imune, inflamatória e de condição de pele
WO2002062352A2 (en) * 2001-02-07 2002-08-15 Durect Corporation Devices and methods for management of bone density
US20030009145A1 (en) * 2001-03-23 2003-01-09 Struijker-Boudier Harry A.J. Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space

Also Published As

Publication number Publication date
IL164219A0 (en) 2005-12-18
AU2003225053B2 (en) 2006-12-14
US20020183288A1 (en) 2002-12-05
CN100421667C (zh) 2008-10-01
WO2003088976A1 (en) 2003-10-30
CN1646137A (zh) 2005-07-27
EP1499324A4 (en) 2008-11-12
JP2005526833A (ja) 2005-09-08
EP1499324A1 (en) 2005-01-26
US20090137536A1 (en) 2009-05-28
AU2003225053A1 (en) 2003-11-03
KR20040101530A (ko) 2004-12-02
CA2481120A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
MXPA04010054A (es) Metodo para tratar y prevenir hiperparatiroidismo.
IN2006KO01346A (es)
TW200510927A (en) Stimulus-sensitive composition, compound and pattern formation method using the stimulation-sensitive composition
MX2007006084A (es) Composiciones y metodos de recubrimiento.
IL173002A (en) Use of calcitonin in the manufacture of oral medication for the prevention or treatment of osteoarthritis
CA2522564A1 (en) Method for emitting volatile compositions
EP2082738A8 (en) Use of beta-hydroxy-beta-methylbutyrate to treat asthma
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
DK1082298T3 (da) 1-alfa-hydroxy-25-en-vitamin D, analoger og anvendelser deraf
MXPA05011068A (es) Sistemas para emitir composiciones volatiles.
WO2004056315A3 (en) Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
HK1083216A1 (en) Terapeutic piperazine compounds
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
WO2004080467A3 (en) Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
WO2003080566A3 (en) Hif hydroxylase inhibitors
RS20060320A (en) Substituted indazole-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA03011173A (es) Composicion de tratamiento de superficie substratos blandos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal